Bambusa Therapeutics reports new shareholder stakes via Schedule 13G, indicating potential shifts in corporate governance and investor interest.
| Name | Bambusa Therapeutics, Inc. |
|---|---|
| CIK | 0002044950 |
| Tickers | BBTX |
| Exchanges | Nasdaq |
| Entity type | other |
| Category | — |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 992083913 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (617) 848-6188 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Bambusa Therapeutics reports new shareholder stakes via Schedule 13G, indicating potential shifts in corporate governance and investor interest.
Bambusa Therapeutics reports significant stock transactions by key investors, reflecting confidence in the biological products industry.
Bambusa Therapeutics announces its IPO, offering 10.6 million shares at $16 each, marking a significant step in the biological products industry.
Bambusa Therapeutics, Inc. has received SEC effectiveness for its S-1 registration statement, paving the way for its capital-raising efforts.
Bambusa Therapeutics expands its public offering by registering over 1.3 million additional shares, reflecting confidence in the biological products sector.
Bambusa Therapeutics has filed a report revealing stock options granted to director Liang Howard, indicating a strategic move to align executive interests with shareholders.
Bambusa Therapeutics reveals insider transactions involving its Series A-1 and A-2 Preferred Stock, signaling investor confidence ahead of IPO.
Bambusa Therapeutics, Inc. announces significant ownership changes involving Helmut Wolfgang Jeggle, impacting the biological products industry.
Bambusa Therapeutics CFO Jonathan Lieber files Form 3, indicating a change in ownership. The move underscores transparency in corporate governance.
Bambusa Therapeutics has filed a certification with the SEC, signaling progress in its business development in the biological products sector.
Bambusa Therapeutics, Inc. has registered its common stock with the SEC, paving the way for a public offering and impacting the biological products industry.
Bambusa Therapeutics, Inc. has filed an amendment for its IPO, signaling its entry into the public market and potential growth in the biological products sector.
Bambusa Therapeutics, Inc. has filed for an initial public offering, aiming to raise capital and enter the public market under the symbol 'BBTX.'
30 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001346824-26-000253 | 005-96002 | 261532230 | 34 | 29333 | |||
| 2026-11-05 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002085929-26-000014 | 005-96002 | 261529050 | 34 | 135993 | |||
| 2026-11-03 | 4 | xslF345X06/form4-11032026_111149.xml | 0001231919-26-001533 | 31115 | ||||||
| 2026-11-03 | 8-K | 8-K | 5.03,7.01,9.01 | 0001628280-26-069027 | 001-43521 | 261513873 | 34 | 286430 | ||
| 2026-11-02 | 4 | xslF345X06/form4-11022026_091107.xml | 0002162499-26-000004 | 13303 | ||||||
| 2026-11-02 | 4 | xslF345X06/form4-11022026_091105.xml | 0001982614-26-000004 | 13507 | ||||||
| 2026-11-02 | 4 | xslF345X06/form4-11022026_091124.xml | 0002160743-26-000013 | 21891 | ||||||
| 2026-11-02 | 4 | xslF345X06/form4-11022026_091130.xml | 0002160743-26-000012 | 8927 | ||||||
| 2026-10-30 | 424B4 | 424B4 | 0001628280-26-068563 | 333-299405 | 261507976 | 33 | 50128333 | |||
| 2026-10-30 | S-8 | S-8 | 0001628280-26-068355 | 333-299709 | 261503600 | 33 | 797862 | 1 | 1 | |
| 2026-10-29 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-003375 | 333-299405 | 261504250 | 33 | 1721 | ||
| 2026-10-29 | S-1MEF | S-1MEF | 0001628280-26-068311 | 333-299707 | 261502921 | 33 | 226354 | 1 | 1 | |
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081024.xml | 0002162499-26-000002 | 8053 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081018.xml | 0001231919-26-001513 | 16608 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081007.xml | 0001982614-26-000002 | 14655 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081036.xml | 0001663427-26-000003 | 11324 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081028.xml | 0001792061-26-000002 | 9598 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081016.xml | 0002160666-26-000002 | 9737 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081014.xml | 0001350090-26-000003 | 11260 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081013.xml | 0002159278-26-000002 | 19552 | ||||||
| 2026-10-29 | 3 | xslF345X06/form3-10292026_081006.xml | 0002160743-26-000009 | 30691 | ||||||
| 2026-10-29 | CERT | 8A_Cert_BBTX_2044950.pdf | 0001354457-26-001035 | 001-43521 | 261499739 | 34 | 181813 | |||
| 2026-10-27 | 8-A12B | 8-A12B | 0001628280-26-067557 | 001-43521 | 261490142 | 34 | 15625 | |||
| 2026-10-26 | S-1/A | S-1/A | 0001628280-26-067119 | 333-299405 | 261483388 | 33 | 52856051 | 1 | 1 | |
| 2026-10-09 | S-1 | S-1 | 0001628280-26-065557 | 333-299405 | 261453641 | 33 | 56730203 | 1 | 1 | |
| 2026-09-15 | DRS/A | filename1.htm | 0001628280-26-061935 | 377-09638 | 261378765 | 33 | 57036769 | |||
| 2026-08-03 | DRS | filename1.htm | 0001628280-26-051869 | 377-09638 | 261233127 | 33 | 19150730 | |||
| 2025-02-26 | D | xslFormDX01/primary_doc.xml | 06b | 0002044950-25-000003 | 021-539297 | 25669272 | 33 | 8204 | ||
| 2025-01-08 | D | xslFormDX01/primary_doc.xml | 06b | 0002044950-25-000002 | 021-534582 | 25517912 | 33 | 6642 | ||
| 2025-01-08 | D | xslFormDX01/primary_doc.xml | 06b | 0002044950-25-000001 | 021-534581 | 25517894 | 33 | 6642 |
One latest value per concept from companyfacts (5 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ffd | NetFeeAmt | NetFeeAmt | USD | 11,690.67 | 2026-10-29 | S-8 | 2026-10-30 | 0001628280-26-068355 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 11,690.67 | 2026-10-29 | S-8 | 2026-10-30 | 0001628280-26-068355 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 134.38M | 2026-10-29 | S-8 | 2026-10-30 | 0001628280-26-068355 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-29 | S-8 | 2026-10-30 | 0001628280-26-068355 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-29 | S-1MEF | 2026-10-29 | 0001628280-26-068311 |